^
Association details:
| Biomarker: | ER positive + HER-2 negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | doxorubicin hydrochloride (Topoisomerase II inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Role of chromosomal instability and clonal heterogeneity in the therapy response of breast cancer cell lines
Published date:
11/15/2020
Excerpt:
ERα+/HER2- cells with intermediate CIN were sensitive to treatment with taxanes (DOC) and anthracyclines (DOX), while ERα-/HER2-, ERα+/HER2+, and ERα-/HER2+ cells with intermediate CIN were resistant to these treatments….A greater understanding of CIN and CH in BC could assist in the optimization of existing therapeutic regimens and/or in supporting new strategies to improve cancer outcomes.
DOI:
10.20892/j.issn.2095-3941.2020.0028
